Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
Dow Jones Industrial Average
) is trading down 30.0 points (-0.2%) at 15,264 as of Friday, May 24, 2013, 12:35 p.m. ET. During this time, 260.2 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 594.1 million. The NYSE advances/declines ratio sits at 947 issues advancing vs. 1,953 declining with 121 unchanged.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Holding back the Dow today is
), which is lagging the broader Dow index with a 47-cent decline (-0.5%) bringing the stock to $86.74. This single loss is lowering the Dow Jones Industrial Average by 3.56 points or roughly accounting for 11.9% of the Dow's overall loss. Volume for Johnson & Johnson currently sits at 5.1 million shares traded vs. an average daily trading volume of 9.8 million shares.
Johnson & Johnson has a market cap of $248.47 billion and is part of the health care sector and drugs industry. Shares are up 24.4% year to date as of Thursday's close. The stock's dividend yield sits at 3%.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The company has a P/E ratio of 24.1, above the S&P 500 P/E ratio of 17.7.
TheStreet Ratings rates Johnson & Johnson as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Johnson & Johnson Ratings Report.
Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE